Navigation Links
Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
Date:7/22/2014

hich has been filed for regulatory approvals in the U.S., Europe and Canada as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid. NKTR-181, a novel mu-opioid analgesic molecule for chronic pain conditions, has completed Phase 2 development. NKTR-171, a new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain, is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of lung and brain cancers. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneumonia. Additional late-stage development products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a longer-acting rFVIII program, which is in Phase 3 clinical development for patients with hemophilia A.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
2. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
3. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
4. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
5. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
6. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
7. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
8. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
9. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
10. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 4, 2015 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug ... in the upcoming Rodman & Renshaw 17 th ... in New York City .  Dr. ... a corporate overview on September 9, 2015. ...
(Date:9/4/2015)... -- Future Prospects for Companies in Antihistamines, ... drugs - new study showing you trends, partnerships, ... for allergic rhinitis drugs heading? What are the commercial ... shows you potential revenues and other trends to 2025, ... page report provides 273 tables, charts, and graphs. Discover ...
(Date:9/4/2015)... 2015 Research and ... of the "Pharmacovigilance (London, UK - December ... Understanding PhV today - the principles and ... Drug safety. This course aims to ... New entrants as well as experienced operators in ...
Breaking Medicine Technology:Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Pharmacovigilance Course: The Principles and Practice of Global PhV for those Working in Drug Safety (London, UK - December 7-9, 2015) 2
... life science tool company developing the third generation of ... over 5 years for the development of rapid, cost-effective ... grant, from the National Institute of Biomedical Imaging and ... will fund the project. QuantaLife is currently ...
... PCYC ) today reported financial results for its fiscal year ... During the fiscal year ended June 30, 2010, total revenue recognized ... fiscal year ended June 30, 2009.  The GAAP net loss reported ... or $0.31 per share. This compares to a GAAP net loss ...
Cached Medicine Technology:Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 2Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 3Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 4Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 5Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 6Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 7Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 8Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 9Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 10Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 11Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 12Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 13Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 14
(Date:9/3/2015)... ... September 03, 2015 , ... While bariatric surgeon Michael Feiz, M.D., F.A.C.S. ... preparing for a bariatric procedure, some patients have been recently asking further questions relating ... typical for many types of surgery that should be followed in the days prior ...
(Date:9/3/2015)... CA (PRWEB) , ... September 03, 2015 , ... TransPack ... X. Users can choose from wipes and framing transitions in 30 different styles. ... made exclusively for Final Cut Pro X. , TransPack Toon features 90 cartoon transitions ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... William Mattar ... William Mattar, Esq. believes this does not stop at any certain demographic or segment ... its newly produced one-minute, thirty-, fifteen- and ten-second TV commercials. , The closed captioning ...
(Date:9/3/2015)... ... September 03, 2015 , ... E-Volve ... a leading national healthcare solutions organization, to provide electronic medical record (EMR) consulting ... agreement, Amerinet members will receive negotiated pricing on E-Volve Health’s Epic EMR consulting, ...
(Date:9/3/2015)... ... September 03, 2015 , ... Mayo School of ... chosen Center for Hospice Care (CHC) for physician Hospice and Palliative Medicine ... as part of fulfilling their requirements for obtaining national Board Certification in Hospice ...
Breaking Medicine News(10 mins):Health News:Dr. Feiz and Associates Answer August's ‘Patient Submitted Question of the Month’: “How Can I Prepare for Weight Loss Surgery” 2Health News:Pixel Film Studios Releases TransPack Toon, a New FCPX Transition 2Health News:Law Firm Focused on “Helping People” Continues to Expand on Vision 2Health News:E-Volve Health to Offer EMR Consulting Solutions to Amerinet Members 2Health News:Physicians from Mayo Clinic and Indiana University to Complete Hospice & Palliative Medicine Training at Center for Hospice Care 2
... In addition to the proposed ban on public smoking, which will ... the age limit of smokers from 16 to 18 years. ... start operating from October 2007. It would then be illegal to ... after 100 years of permitting sale of cigarettes to those over ...
... No Santa could have delivered a more welcome gift. ,Two-year-old Markus ... part of his father’s. , The operation was carried ... , A year ago Markus developed jaundice as a tumor ... orange. , He was put on an organ transplant list ...
... India working in hospitals in north Liverpool have recently been ... of their flats//, according to reports from Liverpool. ... nurses recruited by the National Health Service reside, have been ... to be getting worse. ,Minu Subash, a nurse ...
... Association (BMA) plans collaboration with the Indian Medical Association (IMA) ... medical graduates to train in Britain. ,BMA president Praveen ... national conference of the IMA, said: "I had a fruitful ... was eager for a close and active collaboration with the ...
... Stavis, 52, was able to eat the same pumpkin pie ... And when dinner was over, he didn’t have to reach ... transplant performed at Cedars-Sinai Medical Center in late October cured ... years. ,Oh, and a heart and kidney transplant ...
... caused irreparable damage to his kidneys and forced him to go ... Eliud was in Los Angeles, where he lives, and Jacqueline Lopez ... get the two together. ,Three Christmases ago, Eliud, who ... and 5, was healthy and active, working as a car detailer. ...
Cached Medicine News:Health News:Once-Diabetic Heart/Kidney/Pancreas Transplant Recipient Enjoys Life (And Eating Again) 2Health News:Once-Diabetic Heart/Kidney/Pancreas Transplant Recipient Enjoys Life (And Eating Again) 3Health News:Family and Friends Team Up to Provide LA Man With Kidney Transplant 2
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 110o. Most popular size or model....
Double ended with 0.5 mm x 10 mm and 0.5 mm x 15 mm blades. Both blades gently curved. Square serrated handle with polished finish. Most popular size or model....
11 mm angled tip with gently curved blade. Flat serrated handle with polished finish....
Angled tip with gently curved blade. Short hexagonal handle with polished finish. 0.5 mm x 15 mm tip....
Medicine Products: